Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
Insider Trading Alert: Roger Adsett, Chief Operating Officer of Insmed, executed significant stock sales on June 16, 2025, through a pre-planned 10b5-1 trading arrangement established on March 4, 2025.
Transaction Details:
- First transaction: Sold 6,500 shares at weighted average price of $98.50 (range: $97.93-$98.92)
- Second transaction: Sold 4,186 shares at weighted average price of $99.32 (range: $98.94-$99.83)
- Total shares disposed: 10,686 shares
- Remaining holdings: 130,637 shares held directly
The transactions were executed under a Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations by establishing predetermined trading parameters. All shares are held in direct ownership form.